2025
GlycoEra Raises $130M to Advance Protein Degraders Toward Clinic
GlycoEra; protein degraders; $130 million funding; autoimmune diseases; GE8820; IgG4 autoantibodies; Novo Holdings; clinical trial; precision immunology
Boundless Bio Lays Off 33% of Staff Following Stumble of Lead Program
Boundless Bio; layoffs; biotech; clinical trial; BBI-355; BBI-825; RNR inhibitor; CHK1 inhibitor; combination therapy; solid tumors; pipeline restructuring
Prothena Halts Drug and Plans Major Layoffs After Second Rare Disease Trial Failure
Prothena; birtamimab; AL amyloidosis; Phase III trial; drug failure; layoffs; biotech; spending cuts; business options
About 5% of CBER and CDER Left After FDA Staff Cuts, Analysis Finds
FDA layoffs; CBER; CDER; drug review; biologics; staff cuts; Trump administration; drug approval process
Merus Phase 2 Data: Analysts See Strong Survival in Head & Neck Cancer, ‘Home Run’ Hopes Emerge
Merus; petosemtamab; Phase 2; overall survival; head and neck cancer; Pembrolizumab; Keytruda; clinical trial; analyst reaction; home run scenario
Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025
Jazz Pharmaceuticals; Zepzelca; lurbinectedin; lung cancer; small cell lung cancer; Tecentriq; atezolizumab; IMforte trial; overall survival; progression-free survival; ASCO 2025
GLP-1s May Lower Cancer Risk; Gyre Stock Drops After Hep B Data, Share Offering
GLP-1 receptor agonists; cancer risk; obesity-related cancers; Gyre stock; hepatitis B; clinical data; mortality
Will Trump’s Tax Bill Cut Medicare by $490 Billion? Not Exactly.
Trump tax bill; Medicare cuts; sequestration; budget reconciliation; 2025 healthcare changes; CBO report
Sanofi Opens $130M ‘Flagship’ US Office Facility in Morristown, New Jersey
Sanofi; Morristown; flagship office; $130 million; healthcare; innovation; New Jersey; US market; corporate hub
Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer’s Drug Pipeline
Sanofi; Vigil Neuroscience; acquisition; Alzheimer’s disease; TREM2 agonist; VG-3927; microglia; neurodegenerative disease; Phase 2 trials; biotech deals